Sight Sciences Announces First Patient Treated in TRIDENT European Trial to Evaluate the OMNI® Surgical System in Pseudophakic Eyes with Open-Angle Glaucoma
24 mars 2022 16h04 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and...
Sight Sciences Announces Appointment of Brenda Becker to Board of Directors
16 mars 2022 08h00 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and...
Sight Sciences to Report Fourth Quarter and Full Year 2021 Financial Results on March 24, 2022
03 mars 2022 16h05 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and...
Sight Sciences Announces Multiple Presentations at the 2022 American Glaucoma Society Annual Meeting
02 mars 2022 08h00 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and...
Sight Sciences to Participate in the Upcoming Citi Virtual Healthcare Conference
21 févr. 2022 16h05 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., Feb. 21, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of...
Sight Sciences Launches “Don’t Wait for Too Late” Awareness Campaign for Glaucoma
17 févr. 2022 08h00 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of...
Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Financial Results
10 janv. 2022 05h50 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of...
Sight Sciences Receives FDA 510(k) Clearance of the TearCare® System for Treatment of Meibomian Gland Dysfunction (MGD), the Leading Cause of Dry Eye Disease
22 déc. 2021 08h00 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of...
Sight Sciences to Participate in the Upcoming Piper Sandler Annual Healthcare Conference
18 nov. 2021 16h05 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of...
Microinvasive Glaucoma Surgery with the OMNI® Surgical System is Associated with Diminished Diurnal IOP Fluctuations, a Significant, Independent Risk Factor for Glaucoma Progression
17 nov. 2021 08h00 HE
|
Sight Sciences, Inc.
MENLO PARK, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of...